Literature DB >> 21544490

HLA class I antigens are possible prognostic factors in hepatocellular carcinoma.

M Nishibe1, Y Une, M Kobayashi, Y Kuramitsu, M Hosokawa, J Uchino.   

Abstract

Thirty patients who underwent hepatectomy for the treatment of hepatocellular carcinoma (HCC) were examined for expression of HLA class I antigens on HCC cells by flow cytometry. The expression was found significantly lower in cases of stage IV compared with those of stage I or stage II (p<0.05), and in cases of intrahepatic metastases compared with those without metastases (p<0.001). In cases of non-curative hepatectomy, the expression of HLA class I antigens was lower compared with those treated by curative resection. Postoperative cumulative disease-free survival rates were well correlated with the expression rate of HLA class I antigens (p<0.05). Expression of HLA class I antigens on HCC may indicate low malignancy and better prognosis.

Entities:  

Year:  1996        PMID: 21544490     DOI: 10.3892/ijo.8.6.1243

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.

Authors:  Yuichiroh Umemoto; Shinji Okano; Yoshihiro Matsumoto; Hidekazu Nakagawara; Rumi Matono; Shohei Yoshiya; Yo-Ichi Yamashita; Tomoharu Yoshizumi; Toru Ikegami; Yuji Soejima; Mamoru Harada; Shinichi Aishima; Yoshinao Oda; Ken Shirabe; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2014-02-08       Impact factor: 7.527

2.  Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes.

Authors:  Yu Akazawa; Daisuke Nobuoka; Mari Takahashi; Toshiaki Yoshikawa; Manami Shimomura; Shoichi Mizuno; Toshiyoshi Fujiwara; Yasunari Nakamoto; Tetsuya Nakatsura
Journal:  Cancer Sci       Date:  2019-05-18       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.